Merck faced revenue declines in key areas like GARDASIL and cholesterol products, leading to downward guidance adjustments. While there is growth in other segments such as JANUVIA and ISENTRESS, the overall outlook remains cautious amidst ongoing restructuring efforts. These mixed signals are likely to exert short-term downward pressure on the stock.

[-1]